Table 3.
Coronary dilations stratified by medications commonly prescribed to patients in obese or non-obese patients
| |
BMI ≥ 30 |
BMI < 30 |
||||
|---|---|---|---|---|---|---|
| |
Bradykinin response [10-8M] -% dilation (Std. Error) |
Bradykinin response [10-8M] -% dilation (Std. Error) |
||||
| (+) Drug | (-) Drug | P Value | (+) Drug | (-) Drug | P Value | |
|
ACE inhibitor |
63.5 (9.5) |
51.0 (5.3) |
0.237 |
33.5 (6.2) |
58.2 (5.8) |
0.007 |
|
Angiotensin receptor blocker |
55.1 (6.1) |
54.1 (7.2) |
0.919 |
64.4 (8.1) |
36.9 (5.1) |
0.007 |
|
Aspirin |
57.1 (4.8) |
43.1 (14.6) |
0.261 |
49.2 (5.3) |
30.5 (9.2) |
0.086 |
|
Statin |
58.3 (4.7) |
50.4 (8.6) |
0.412 |
53.7 (5.1) |
20.1 (6.0) |
0.001 |
|
Insulin |
48.3 (7.6) |
56.3 (5.6) |
0.492 |
57.9 (10.3) |
41.3 (5.2) |
0.165 |
|
Anti-diabetics |
62.0 (23.0) |
52.6 (5.1) |
0.424 |
46.2 (11.5) |
44.1 (5.3) |
0.867 |
|
Beta blocker |
89.3% of obese patients are on beta blockers; test not valid |
51.5 (5.7) |
34.8 (7.6) |
0.081 |
||
|
Diuretic |
50.3 (9.8) |
55.8 (5.4) |
0.641 |
52.3 (6.0) |
38.9 (6.7) |
0.166 |
|
Calcium channel blocker |
55.8 (7.6) |
53.5 (6.1) |
0.811 |
38.6 (7.2) |
49.2 (6.2) |
0.267 |
|
H+ blocker |
62.0 (6.8) |
49.8 (62.6) |
0.210 |
45.8 (7.9) |
44.3 (5.5) |
0.907 |
| Nitrate | 59.9 (8.6) | 52.5 (5.7) | 0.487 | 11.1% of non-obese patients are on nitrates; test not valid | ||
BMI – body mass index; ACE – angiotensin converting enzyme; ARB – angiotensin receptor blocker; CCB – calcium channel blocker, Significance determined by 1-Way ANOVA. Data is presented as the mean ± standard deviation.